How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

14,108 results for

Chronic Leukemia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

8. Venclexta for Chronic Lymphocytic Leukemia – Details

Venclexta for Chronic Lymphocytic Leukemia – Details Venclexta for Chronic Lymphocytic Leukemia – Details | CADTH.ca Find the information you need Venclexta for Chronic Lymphocytic Leukemia – Details Venclexta for Chronic Lymphocytic Leukemia – Details Project Number pCODR 10105 Brand Name Venclexta Generic Name Venetoclax Strength 10mg, 50 mg & 100mg tablet Tumour Type Leukemia Indication Chronic Lymphocytic Leukemia Funding Request As monotherapy for the treatment of patients with chronic (...) lymphocytic leukemia (CLL) who have received at least one prior therapy and who have failed a B-Cell Receptor Inhibitor (BCRi) Review Status Notification to Implement Issued Pre Noc Submission No NOC Date September 30, 2016 Manufacturer AbbVie Corporation Submitter AbbVie Corporation Submission Date July 10, 2017 Submission Deemed Complete July 17, 2017 Submission Type New Indication Prioritization Requested Requested and Granted Stakeholder Input Deadline ‡ July 24, 2017 Check-point meeting September 7

2018 CADTH - Pan Canadian Oncology Drug Review

9. Venclexta for Chronic Lymphocytic Leukemia – Details

Venclexta for Chronic Lymphocytic Leukemia – Details Venclexta for Chronic Lymphocytic Leukemia – Details | CADTH.ca Find the information you need Venclexta for Chronic Lymphocytic Leukemia – Details Venclexta for Chronic Lymphocytic Leukemia – Details Project Number pCODR 10105 Brand Name Venclexta Generic Name Venetoclax Strength 10mg, 50 mg & 100mg tablet Tumour Type Leukemia Indication Chronic Lymphocytic Leukemia Funding Request As monotherapy for the treatment of patients with chronic (...) lymphocytic leukemia (CLL) who have received at least one prior therapy and who have failed a B-Cell Receptor Inhibitor (BCRi) Review Status Notification to Implement Issued Pre Noc Submission No NOC Date September 30, 2016 Manufacturer AbbVie Corporation Submitter AbbVie Corporation Submission Date July 10, 2017 Submission Deemed Complete July 17, 2017 Submission Type New Indication Prioritization Requested Requested and Granted Stakeholder Input Deadline ‡ July 24, 2017 Check-point meeting September 7

2017 CADTH - Pan Canadian Oncology Drug Review

10. Chronic myelogenous leukemia occurring in a chronic lymphocytic leukemia patient (PubMed)

Chronic myelogenous leukemia occurring in a chronic lymphocytic leukemia patient Occurrence of two different hematological malignancies is very infrequent, and it is nevertheless important not to neglect basic examinations in patients follow-up. A 65-year-old patient was referred to our institution for his chronic lymphocytic leukemia (CLL) checkup; we report the different steps leading to the diagnosis of a second hematological malignancy.

Full Text available with Trip Pro

2018 Clinical Case Reports

11. Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature (PubMed)

Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature Chronic lymphocytic leukemia and chronic myeloid leukemia are the most common types of adult leukemia. However, it is rare for the same patient to suffer from both. Richter's transformation to diffuse large B-cell lymphoma is frequently observed in chronic lymphocytic leukemia. Purine analog therapy and the presence of trisomy 12 (...) , and CCND1 gene rearrangement have been linked to increased risk of Richter's transformation. The coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma in the same patient is extremely rare, with only nine reported cases. Here, we describe the first reported case of concurrent chronic myeloid leukemia and diffuse large B-cell lymphoma in a background of chronic lymphocytic leukemia.A 60-year-old Saudi man known to have diabetes, hypertension, and chronic active hepatitis B

Full Text available with Trip Pro

2018 Journal of medical case reports

12. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group. (PubMed)

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group. The ultimate goal of chronic myeloid leukemia management in the tyrosine kinase inhibitor (TKI) era for patients who obtain deep molecular responses is maintaining a durable off-treatment response after treatment discontinuation; this situation is called treatment-free remission (TFR). Knowledge accumulated during the last 10 (...) years justifies moving TFR strategies from research to clinical practice.Twenty experts from the French Chronic Myeloid Leukemia Study Group (France Intergroupe des Leucémies Myéloïdes Chroniques), including 17 hematologists, 2 molecular biologists, and 1 cytogeneticist, critically reviewed published data with the goal of developing evidence-based recommendations for TKI discontinuation in clinical practice.Clinically relevant questions were addressed, including the selection of candidate patients

2018 Cancer

13. Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. (PubMed)

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. Standard first-line therapy of chronic myeloid leukemia is treatment with imatinib. In the randomized German Chronic Myeloid Leukemia-Study IV, more potent BCR-ABL inhibition with 800mg (high-dose) imatinib accelerated achievement of a deep molecular remission. However, whether and when a de-escalation of the dose intensity under high-dose imatinib can (...) be safely performed without increasing the risk of losing deep molecular response is unknown. To gain insights into this clinically relevant question, we analyzed the outcome of imatinib dose reductions from 800mg to 400mg daily in the Chronic Myeloid Leukemia-Study IV. Of the 422 patients that were randomized to the 800mg arm, 68 reduced imatinib to 400mg after they had achieved at least a stable major molecular response. 61 of these 68 patients (90%) maintained major molecular remission on imatinib

Full Text available with Trip Pro

2018 Haematologica

14. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study. (PubMed)

Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study. Treatment-free remission (TFR)-that is, stopping tyrosine kinase inhibitor (TKI) therapy without loss of response-is an emerging treatment goal in chronic myeloid leukemia (CML).To evaluate TFR after discontinuation of second-line nilotinib therapy.Single-group, phase 2, open-label study. (ClinicalTrials.gov (...) : NCT01698905).63 centers in 18 countries.Adults with CML in chronic phase who received TKI therapy for at least 3 years (>4 weeks with imatinib, then ≥2 years with nilotinib) and achieved MR4.5 (BCR-ABL1 ≤0.0032% on the International Scale [BCR-ABL1IS]) while receiving nilotinib entered a 1-year consolidation phase. Those with sustained MR4.5 during consolidation were eligible to enter TFR.Patients received nilotinib during consolidation; those who entered TFR stopped treatment. Patients with loss of major

2018 Annals of Internal Medicine

15. Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. (PubMed)

Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. 26962747 2016 03 15 2018 07 30 1533-4406 374 10 2016 03 10 The New England journal of medicine N. Engl. J. Med. Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor (...) T Cells for Sustained Remissions in Leukemia. 998 10.1056/NEJMx160005 eng Journal Article Published Erratum United States N Engl J Med 0255562 0028-4793 N Engl J Med. 2011 Aug 25;365(8):725-33 21830940 N Engl J Med. 2013 Apr 18;368(16):1509-1518 23527958 N Engl J Med. 2014 Oct 16;371(16):1507-17 25317870 2016 3 11 6 0 2016 3 11 6 0 2016 3 11 6 1 ppublish 26962747 10.1056/NEJMx160005

Full Text available with Trip Pro

2016 NEJM

16. Comparative effectiveness review of the influence of stem cell source on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia

Comparative effectiveness review of the influence of stem cell source on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia Comparative effectiveness review of the influence of stem cell source on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia Comparative effectiveness review of the influence of stem cell source on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia (...) HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Comparative effectiveness review of the influence of stem cell source on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia. Lansdale: HAYES, Inc.. Directory Publication. 2016 Authors' conclusions Patients with chronic myelogenous leukemia (CML

2016 Health Technology Assessment (HTA) Database.

17. Comparative effectiveness review of influence of pretransplant treatment and conditioning strategies on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia

Comparative effectiveness review of influence of pretransplant treatment and conditioning strategies on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia Comparative effectiveness review of influence of pretransplant treatment and conditioning strategies on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia Comparative effectiveness review of influence of pretransplant treatment and conditioning strategies (...) on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Comparative effectiveness review of influence of pretransplant treatment and conditioning strategies on allogeneic stem cell transplant effectiveness for treatment of chronic myelogenous leukemia. Lansdale

2016 Health Technology Assessment (HTA) Database.

18. Comparative effectiveness of allogeneic hematopoietic stem cell transplant versus drug-based strategies for treatment of chronic myelogenous leukemia

Comparative effectiveness of allogeneic hematopoietic stem cell transplant versus drug-based strategies for treatment of chronic myelogenous leukemia Comparative effectiveness of allogeneic hematopoietic stem cell transplant versus drug-based strategies for treatment of chronic myelogenous leukemia Comparative effectiveness of allogeneic hematopoietic stem cell transplant versus drug-based strategies for treatment of chronic myelogenous leukemia HAYES, Inc. Record Status This is a bibliographic (...) record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Comparative effectiveness of allogeneic hematopoietic stem cell transplant versus drug-based strategies for treatment of chronic myelogenous leukemia. Lansdale: HAYES, Inc.. Directory Publication. 2016 Authors' conclusions Patients with chronic myelogenous leukemia (CML) have an overproduction of partially mature white blood cells of the myeloid

2016 Health Technology Assessment (HTA) Database.

19. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study The MURANO study demonstrated significant progression-free survival (PFS) benefit for fixed-duration venetoclax-rituximab compared with bendamustine-rituximab in relapsed/refractory chronic lymphocytic leukemia. With all patients off treatment, we report minimal residual disease (MRD) kinetics

2019 EvidenceUpdates

20. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia

Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia Ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase, is an effective therapy for patients with chronic lymphocytic leukemia (CLL). To determine whether rituximab provides added benefit to ibrutinib, we conducted a randomized single-center trial of ibrutinib vs ibrutinib plus rituximab. Patients with CLL requiring therapy were randomized to receive 28-day cycles of once-daily

2019 EvidenceUpdates

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>